Rick Bangs

Also affiliated with SWOG Cancer Research Network

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 15 papers. Top paper: “Phase 2 Trial of Atezolizumab in Bacillus Calmette-Guérin–unresponsive High-risk Non–muscle-invasive Bladder Cancer: SWOG S1605”.

Phase 2 Trial of Atezolizumab in Bacillus Calmette-Guérin–unresponsive High-risk Non–muscle-invasive Bladder Cancer: SWOG S1605

European Urology(2023)10.1016/j.eururo.2023.08.004

N/A

2.9DataRank · unranked

93 citations

Catherine M. Tangen, Parminder Singh, David J. McConkey, M. Scott Lucia, William T. Lowrance +10 more

A Randomized Phase II Study of Coexpression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Bladder Cancer (SWOG S1314; NCT02177695)

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-20-2409

N/A

2.8DataRank · unranked

92 citations

Catherine M. Tangen, Siamak Daneshmand, Ajjai Alva, Seth P. Lerner, M. Scott Lucia +12 more

Standard or Extended Lymphadenectomy for Muscle-Invasive Bladder Cancer

New England Journal of Medicine(2024)10.1056/nejmoa2401497

N/A

2.4DataRank · unranked

64 citations

Catherine M. Tangen, Robert S. Svatek, Siamak Daneshmand, Kamal S. Pohar, Eila C. Skinner +15 more

Long-term Outcomes from a Phase 2 Study of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer (SWOG S1314; NCT02177695)

European Urology(2023)10.1016/j.eururo.2023.06.014

N/A

0.650DataRank · unranked

20 citations

Catherine M. Tangen, Siamak Daneshmand, Ajjai Alva, M. Scott Lucia, David J. McConkey +12 more

Association of Molecular Subtypes with Pathologic Response, PFS, and OS in a Phase II Study of COXEN with Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-0602

N/A

0DataRank · unranked

19 citations

David J. McConkey, Catherine M. Tangen, Joshua J. Meeks, Thomas W. Flaig, Xing Hua +12 more

Advancing Clinical Trial Design for Non-Muscle Invasive Bladder Cancer

Bladder Cancer(2023)10.3233/blc-230056

N/A

0DataRank · unranked

8 citations

Noah M. Hahn, Seth P. Lerner, Jaleh Fallah, Sundeep Agrawal, Ashish M. Kamat +33 more

SWOG S1011: A phase III surgical trial to evaluate the benefit of a standard versus an extended lymphadenectomy performed at time of radical cystectomy for muscle invasive urothelial cancer.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.4508

N/A

0DataRank · unranked

39 citations

Catherine M. Tangen, Robert S. Svatek, Siamak Daneshmand, Kamal S. Pohar, Eila C. Skinner +15 more

A phase III randomized trial of eribulin (E) with or without gemcitabine vs standard of care (SOC) for metastatic urothelial carcinoma (UC) refractory to or ineligible for PD/PDL1 antibody (Ab): SWOG S1937.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.6_suppl.tps581

N/A

0DataRank · unranked

0 citations

Melissa Plets, Primo N. Lara, Catherine M. Tangen, Rick Bangs, Seth P. Lerner +4 more

A phase III randomized trial of eribulin (E) with or without gemcitabine vs standard of care (SOC) for metastatic urothelial carcinoma (UC) refractory to or ineligible for PD/PDL1 antibody (Ab): SWOG S1937.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.tps4608

N/A

0DataRank · unranked

0 citations

Melissa Plets, Primo N. Lara, Catherine M. Tangen, Rick Bangs, Seth P. Lerner +4 more

Interventions addressing health-related social needs among patients with cancer

JNCI Journal of the National Cancer Institute(2024)10.1093/jnci/djad269

N/A

0DataRank · unranked

24 citations

Simon J. Craddock Lee, Stacy Tessler Lindau, Alyce S. Adams, Brenda A. Adjei, Mary Lou Brown +6 more

End Points for the Next-Generation Bladder-Sparing Perioperative Trials for Patients With Muscle-Invasive Bladder Cancer

Journal of Clinical Oncology(2025)10.1200/jco-25-01608

N/A

0DataRank · unranked

16 citations

Matthew D. Galsky, Nazlı Dizman, David H. Aggen, Neeraj Agarwal, Hikmat Al‐Ahmadie +39 more

Urine Tumor DNA to Stratify the Risk of Recurrence in Patients Treated with Atezolizumab for Bacillus Calmette-Guérin–unresponsive Non–muscle-invasive Bladder Cancer

European Urology(2025)10.1016/j.eururo.2025.03.023

N/A

0DataRank · unranked

15 citations

Parminder Singh, David J. McConkey, M. Scott Lucia, Vadim S. Koshkin, Kelly Stratton +16 more

Phase II trial of atezolizumab in BCG-unresponsive non-muscle invasive bladder cancer: SWOG S1605 (NCT #02844816).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.4541

N/A

0DataRank · unranked

27 citations

Catherine M. Tangen, Parminder Singh, David J. McConkey, Scott Lucia, William T. Lowrance +10 more

SWOG S1314: A randomized phase II study of co-expression extrapolation (COXEN) with neoadjuvant chemotherapy for localized, muscle-invasive bladder cancer with overall survival follow up.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.6_suppl.536

N/A

0DataRank · unranked

5 citations

Catherine M. Tangen, Siamak Daneshmand, Ajjai Alva, M. Scott Lucia, David J. McConkey +12 more

Randomized phase II trial of gemcitabine, avelumab and carboplatin versus no neoadjuvant therapy preceding surgery for cisplatin-ineligible muscle-invasive urothelial carcinoma (MIUC): SWOG GAP trial (S2011).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.6_suppl.tps591

N/A

0DataRank · unranked

1 citations

Melissa Plets, Michael A. Liss, Joshua J. Meeks, Daniel P. Petrylak, Suzanne Cole +9 more